Latus Bio closed a $97 million Series A to advance a broad therapeutics pipeline based on novel AAV capsid variants, funding operations through milestone-driven clinical work. The company expects initial clinical data from two programs: LTS-201 for Huntington’s disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). The Huntington’s focus is notable given prior setbacks in the gene-therapy category when dosing, delivery, and tolerability become tightly constrained. Latus positions its capsid approach as a way to enable efficient delivery at lower doses. The financing also reinforces the continued dominance of AAV platform investments in neurogenetic disease—where capsid engineering can unlock translational improvements even without changing the therapeutic modality. For investors and partnering groups, the near-term milestones around initial clinical data make Latus a candidate for follow-on capital depending on early efficacy and safety signals.